CTRI/2021/07/034906RecruitingPhase 4
A Post Marketing Surveillance (PMS) Study for VPRIV�® (velaglucerase alfa) in India - SHP669-406_VPRIV�® (velaglucerase alfa) - India
Trial Snapshot
- Phase
- Phase 4
- Status
- Recruiting
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Pms
Eligibility Criteria
Inclusion Criteria
- •Patients with Gaucher disease prescribed VPRIV according to the investigators judgment and current Indian PI are eligible for this study. Patient or legally authorized representative must provide written informed consent to participate
Exclusion Criteria
- •Patients will be excluded from this study if the patient met any of the contraindications included
- •in the current Indian PI for VPRIV
Investigators
Similar Trials
Completed
Phase 4
A study to assess the safety and tolerability of VELNEZ nasal pack after nasal surgeryCTRI/2018/04/013227Datt Mediproducts Pvt Ltd37
Completed
Phase 4
A study to assess the safety and tolerability of VELNEZ nasal pack after surgery of noseCTRI/2018/12/016535Datt Mediproducts Pvt Ltd40
Completed
Phase 4
A study (PMS) to check and assess the safety and tolerability of a biodegradable nasal dressing (VELNEZ) after nose surgery.CTRI/2021/09/036437Datt Mediproducts Pvt Ltd20
Active, not recruiting
Phase 4
A prospective, Post Marketing Surveillance study of omalizumab in Chronic Spontaneous UrticariaCTRI/2015/10/006247ovartis Healthcare Private Limited
Completed
Not Applicable
Post Marketing Surveillance (PMS) Study for Velaglucerase Alfa (VPRIV) in IndiaGaucher DiseaseNCT04429984Shire21